vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). Tecnoglass Inc. runs the higher net margin — 10.6% vs 1.6%, a 9.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 2.4%). Over the past eight quarters, Tecnoglass Inc.'s revenue compounded faster (12.8% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
PCRX vs TGLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $245.3M |
| Net Profit | $2.9M | $26.1M |
| Gross Margin | — | 40.0% |
| Operating Margin | 3.9% | 18.3% |
| Net Margin | 1.6% | 10.6% |
| Revenue YoY | 5.0% | 2.4% |
| Net Profit YoY | — | -44.5% |
| EPS (diluted) | $0.07 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $245.3M | ||
| Q3 25 | $179.5M | $260.5M | ||
| Q2 25 | $181.1M | $255.5M | ||
| Q1 25 | $168.9M | $222.3M | ||
| Q4 24 | $187.3M | $239.6M | ||
| Q3 24 | $168.6M | $238.3M | ||
| Q2 24 | $178.0M | $219.7M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $26.1M | ||
| Q3 25 | $5.4M | $47.2M | ||
| Q2 25 | $-4.8M | $44.1M | ||
| Q1 25 | $4.8M | $42.2M | ||
| Q4 24 | — | $47.0M | ||
| Q3 24 | $-143.5M | $49.5M | ||
| Q2 24 | $18.9M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 40.0% | ||
| Q3 25 | 80.9% | 42.7% | ||
| Q2 25 | 77.4% | 44.7% | ||
| Q1 25 | 79.7% | 43.9% | ||
| Q4 24 | 78.7% | 44.5% | ||
| Q3 24 | 76.9% | 45.8% | ||
| Q2 24 | 75.1% | 40.8% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 18.3% | ||
| Q3 25 | 3.5% | 25.1% | ||
| Q2 25 | 4.7% | 24.0% | ||
| Q1 25 | 1.2% | 26.7% | ||
| Q4 24 | 13.2% | 28.0% | ||
| Q3 24 | -82.8% | 28.4% | ||
| Q2 24 | 15.9% | 23.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 10.6% | ||
| Q3 25 | 3.0% | 18.1% | ||
| Q2 25 | -2.7% | 17.3% | ||
| Q1 25 | 2.8% | 19.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | -85.1% | 20.8% | ||
| Q2 24 | 10.6% | 15.9% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.57 | ||
| Q3 25 | $0.12 | $1.01 | ||
| Q2 25 | $-0.11 | $0.94 | ||
| Q1 25 | $0.10 | $0.90 | ||
| Q4 24 | $0.38 | $1.00 | ||
| Q3 24 | $-3.11 | $1.05 | ||
| Q2 24 | $0.39 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $104.1M |
| Total DebtLower is stronger | — | $174.4M |
| Stockholders' EquityBook value | $653.9M | $713.1M |
| Total Assets | $1.2B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $104.1M | ||
| Q3 25 | $246.3M | $127.1M | ||
| Q2 25 | $445.9M | $140.9M | ||
| Q1 25 | $493.6M | $160.2M | ||
| Q4 24 | $484.6M | $137.5M | ||
| Q3 24 | $453.8M | $124.8M | ||
| Q2 24 | $404.2M | $129.5M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $174.4M | ||
| Q3 25 | $376.7M | $114.7M | ||
| Q2 25 | $580.5M | $110.6M | ||
| Q1 25 | $583.4M | $110.6M | ||
| Q4 24 | $585.3M | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $713.1M | ||
| Q3 25 | $727.2M | $764.0M | ||
| Q2 25 | $757.8M | $736.0M | ||
| Q1 25 | $798.5M | $685.1M | ||
| Q4 24 | $778.3M | $631.2M | ||
| Q3 24 | $749.6M | $613.3M | ||
| Q2 24 | $879.3M | $574.8M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $996.3M | ||
| Q2 24 | $1.6B | $942.5M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.24× | ||
| Q3 25 | 0.52× | 0.15× | ||
| Q2 25 | 0.77× | 0.15× | ||
| Q1 25 | 0.73× | 0.16× | ||
| Q4 24 | 0.75× | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $31.0M |
| Free Cash FlowOCF − Capex | — | $11.4M |
| FCF MarginFCF / Revenue | — | 4.7% |
| Capex IntensityCapex / Revenue | — | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $31.0M | ||
| Q3 25 | $60.8M | $40.0M | ||
| Q2 25 | $12.0M | $17.9M | ||
| Q1 25 | $35.5M | $46.9M | ||
| Q4 24 | $33.1M | $61.1M | ||
| Q3 24 | $53.9M | $41.5M | ||
| Q2 24 | $53.2M | $34.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $11.4M | ||
| Q3 25 | $57.0M | $21.2M | ||
| Q2 25 | $9.3M | $-14.7M | ||
| Q1 25 | $26.9M | $16.5M | ||
| Q4 24 | $31.0M | $35.4M | ||
| Q3 24 | $49.8M | $17.8M | ||
| Q2 24 | $51.6M | $14.2M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 4.7% | ||
| Q3 25 | 31.7% | 8.2% | ||
| Q2 25 | 5.1% | -5.7% | ||
| Q1 25 | 15.9% | 7.4% | ||
| Q4 24 | 16.6% | 14.8% | ||
| Q3 24 | 29.6% | 7.5% | ||
| Q2 24 | 29.0% | 6.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 8.0% | ||
| Q3 25 | 2.2% | 7.2% | ||
| Q2 25 | 1.5% | 12.7% | ||
| Q1 25 | 5.1% | 13.7% | ||
| Q4 24 | 1.1% | 10.7% | ||
| Q3 24 | 2.4% | 9.9% | ||
| Q2 24 | 0.9% | 9.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.19× | ||
| Q3 25 | 11.20× | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | 7.37× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | 2.82× | 0.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
